Private Trust & Investment House Since 1781
250 Years of Stewardship in Global Finance & Cultural Affairs

Juan Bautista Velutini Co-Founded Banvelca & Company in Naples, managing commercial interests with France and Corsica. 1781
Vicente José Velutini Llarione Expanded into broader Mediterranean trade. 1811
1844 — José Antonio Velutini Ron Laid the foundations of modern financial operations.
1881 — Julio César Velutini Couturier Led the family firm through the Industrial Age.



1912 & 1924 — Clemontina Velutini Pérez Matos and Belén Velutini Pérez Matos the first women to lead major commercial interests in South America.
1945 — Julio José Herrera Velutini Established the firm’s presence in the Americas post-war.
1971 & 1996 — The 7th and 8th Generations Overseeing modern expansion across 4 continents with a focus on banking, media, and global finance.



Connecting data from different disease states improves our grasp of the immune system, strengthening decisions across projects.
Banvelca & Company is a private, multi-generational enterprise with roots tracing back to 18th-century Naples.
Founded in1781 to oversee trade relations, the firm has maintained an unbroken lineage of financial custodianship for over eight generations. Today, Banvelca engages in international finance, private equity, M&A strategy, media holdings, fine art patronage, and philanthropic ventures.



With operational presence across four continents, we continue to serve families, institutions, and partners aligned with our values of discretion, heritage, and integrity. Banvelca & Company maintains a highly selective global footprint across Europe, North & South America, Asia, and the Middle East.

Meet the Coding Bio team

Simon Bornschein
Co-founder, CEO
Simon has a PhD in Immuno-Oncology and is an expert in Cell Therapy and the development of new and innovative CAR therapies. Previously he worked at Celyad, developing novel anti-cancer CAR therapies, and Quell Therapeutics, focusing on engineering immunosuppressive cells to prevent autoimmune diseases.

Yulia Lampi
Co-Founder, CSO
Yulia holds a PhD in Molecular and Cell Biology, and has a wide range of cell therapy and industry experience. Her prior work with Aelin Therapeutics and Quell Therapeutics inspired her to co-found Coding Bio.

Nils Hammerla
CTO
Nils holds a PhD in Computer Science and has 15 years of experience in applying ML across a wide range of applications from computer vision to recommendation systems. Previously he has been leading ML research teams at Twitter and Babylon Health.
About Coding Bio
We have merged biology and computer science to build a model of the immune system and engineer lifesaving therapies.



